↓ Skip to main content

Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake

Overview of attention for article published in Journal of Neuroinflammation, January 2018
Altmetric Badge

Mentioned by

twitter
1 X user

Readers on

mendeley
32 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake
Published in
Journal of Neuroinflammation, January 2018
DOI 10.1186/s12974-017-1048-6
Pubmed ID
Authors

Antonietta Gentile, Alessandra Musella, Francesca De Vito, Diego Fresegna, Silvia Bullitta, Francesca Romana Rizzo, Diego Centonze, Georgia Mandolesi

Abstract

Laquinimod is an immunomodulatory drug under clinical investigation for the treatment of the progressive form of multiple sclerosis (MS) with both anti-inflammatory and neuroprotective effects. Excitotoxicity, a prominent pathophysiological feature of MS and of its animal model, experimental autoimmune encephalomyelitis (EAE), involves glutamate transporter (GluT) dysfunction in glial cells. The aim of this study was to assess whether laquinimod might exert direct neuroprotective effects by interfering with the mechanisms of excitotoxicity linked to GluT function impairments in EAE. Osmotic minipumps allowing continuous intracerebroventricular (icv) infusion of laquinimod for 4 weeks were implanted into C57BL/6 mice before EAE induction. EAE cerebella were taken to perform western blot and qPCR experiments. For ex vivo experiments, EAE cerebellar slices were incubated with laquinimod before performing electrophysiology, western blot, and qPCR. In vivo treatment with laquinimod attenuated EAE clinical score at the peak of the disease, without remarkable effects on inflammatory markers. In vitro application of laquinimod to EAE cerebellar slices prevented EAE-linked glutamatergic alterations without mitigating astrogliosis and inflammation. Moreover, such treatment induced an increase of Slcla3 mRNA coding for the glial glutamate-aspartate transporter (GLAST) without affecting the protein content. Concomitantly, laquinimod significantly increased the levels of the glial glutamate transporter 1 (GLT-1) protein and pharmacological blockade of GLT-1 function fully abolished laquinimod anti-excitotoxic effect. Overall, our results suggest that laquinimod protects against glutamate excitotoxicity of the cerebellum of EAE mice by bursting the expression of glial glutamate transporters, independently of its anti-inflammatory effects.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 32 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 22%
Student > Ph. D. Student 6 19%
Student > Bachelor 3 9%
Student > Doctoral Student 2 6%
Other 2 6%
Other 4 13%
Unknown 8 25%
Readers by discipline Count As %
Neuroscience 6 19%
Biochemistry, Genetics and Molecular Biology 5 16%
Psychology 3 9%
Immunology and Microbiology 2 6%
Nursing and Health Professions 2 6%
Other 5 16%
Unknown 9 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 January 2018.
All research outputs
#20,458,307
of 23,015,156 outputs
Outputs from Journal of Neuroinflammation
#2,325
of 2,654 outputs
Outputs of similar age
#377,939
of 441,866 outputs
Outputs of similar age from Journal of Neuroinflammation
#53
of 64 outputs
Altmetric has tracked 23,015,156 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,654 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 441,866 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 64 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.